# Efficacy and Tolerability of Angeliq in Thai Women

> **NCT00185328** · PHASE4 · COMPLETED · sponsor: **Bayer** · enrollment: 55 (actual)

## Conditions studied

- Postmenopause

## Interventions

- **DRUG:** Estradiol/DRSP (Angeliq, BAY86-4891)

## Key facts

- **NCT ID:** NCT00185328
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-09
- **Primary completion:** —
- **Final completion:** 2006-12
- **Target enrollment:** 55 (ACTUAL)
- **Last updated:** 2008-12-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00185328

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00185328, "Efficacy and Tolerability of Angeliq in Thai Women". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT00185328. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*